ELISA/assay

Mouse Apoprotein B100 ELISA Kit

MBS730575

48-Strip-Wells

470 USD

ELISA Kit

Mouse Apoprotein B100 ELISA Kit

Apoprotein B100

apo-B100; Apolipoprotein B-100; apolipoprotein B-100; apoB-48; apoB-100; apo B-100; mutant Apo B 100; apolipoprotein B48; apolipoprotein B (including Ag(x) antigen); apolipoprotein B

Apo-B100

APOB; APOB; FLDB; LDLCQ4; Apo B-100; Apo B-48

APOB_HUMAN

Mouse

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Sandwich. Sensitivity: 1.0 ng/mL.

Intended Uses: This Apo-B100 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Mouse Apo-B100. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Cardiovascular

Principle of the Assay: Apo-B100 ELISA kit applies the quantitative sandwich enzyme immunoassay technique. The microtiter plate has been pre-coated with a monoclonal antibody specific for Apo-B100. Standards or samples are then added to the microtiter plate wells and Apo-B100 if present, will bind to the antibody pre-coated wells. In order to quantitatively determine the amount of Apo-B100 present in the sample, a standardized preparation of horseradish peroxidase (HRP) -conjugated polyclonal antibody, specific for Apo-B100 are added to each well to "sandwich" the Apo-B100 immobilized on the plate. The microtiter plate undergoes incubation, and then the wells are thoroughly washed to remove all unbound components. Next, substrate solutions are added to each well. The enzyme (HRP) and substrate are allowed to react over a short incubation period. Only those wells that contain Apo-B100 and enzyme-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The Apo-B100 concentration in each sample is interpolated from this standard curve.

28780

CAA28420.1

P04114

515,605 Da

Binding And Uptake Of Ligands By Scavenger Receptors Pathway (771599); Cell Surface Interactions At The Vascular Wall Pathway (106062); Chylomicron-mediated Lipid Transport Pathway (106157); Disease Pathway (530764); Diseases Associated With Visual Transduction Pathway (771581); FOXA1 Transcription Factor Network Pathway (137979); Fat Digestion And Absorption Pathway (194385); Fat Digestion And Absorption Pathway (194324); Hemostasis Pathway (106028); LDL-mediated Lipid Transport Pathway (106159)

This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA- UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Jul 2008]

APOB: Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Defects in APOB are a cause of familial hypobetalipoproteinemia type 1 (FHBL1). A disorder characterized by highly reduced plasma concentrations of low density lipoproteins, and dietary fat malabsorption. Clinical presentation may vary from no symptoms to severe gastrointestinal and neurological dysfunction similar to abetalipoproteinemia. Defects in APOB are a cause of familial ligand-defective apolipoprotein B-100 (FDB). FDB is a dominantly inherited disorder of lipoprotein metabolism leading to hypercholesterolemia and increased proneness to coronary artery disease (CAD). The plasma cholesterol levels are dramatically elevated due to impaired clearance of LDL particles by defective APOB/E receptors. Defects in APOB associated with defects in other genes (polygenic) can contribute to hypocholesterolemia. Protein type: Secreted, signal peptide; Secreted; Carrier. Chromosomal Location of Human Ortholog: 2p24-p23. Cellular Component: Golgi apparatus; extracellular space; endoplasmic reticulum membrane; intracellular membrane-bound organelle; endoplasmic reticulum lumen; early endosome; extracellular region; cytosol; actin cytoskeleton; chylomicron; cell soma; cytoplasm; plasma membrane; endosome membrane. Molecular Function: heparin binding; protein binding; low-density lipoprotein receptor binding; cholesterol transporter activity; phospholipid binding. Biological Process: lipoprotein catabolic process; phototransduction, visible light; response to lipopolysaccharide; response to carbohydrate stimulus; post-embryonic development; response to selenium ion; triacylglycerol catabolic process; retinoid metabolic process; transmembrane transport; cholesterol metabolic process; receptor-mediated endocytosis; nervous system development; cholesterol transport; in utero embryonic development; response to virus; regulation of cholesterol biosynthetic process; lipoprotein metabolic process; cholesterol efflux; cholesterol homeostasis; sperm motility; fertilization; lipoprotein biosynthetic process; lipoprotein transport; artery morphogenesis; spermatogenesis; blood coagulation; triacylglycerol mobilization; leukocyte migration. Disease: Hypercholesterolemia, Autosomal Dominant, Type B; Hypobetalipoproteinemia, Familial, 1

48-Strip-Wells

470 USD

96-Strip-Wells

675